Der wichtigste Partner für Kapitel PHARMACEUTICAL PRODUCTS ist 🇺🇸 Vereinigte Staaten mit einem Volumen von €33.6B im Zeitraum Jan-Mär 2026.
Kapitel PHARMACEUTICAL PRODUCTS weist einen Überschuss von €43.1B auf (Jan-Mär 2026). Die EU importiert €27.0B und exportiert €70.1B.
Das wichtigste NC8-Produkt in Kapitel PHARMACEUTICAL PRODUCTS ist Other (30049000) mit einem Volumen von €39.2B im Zeitraum Jan-Mär 2026.
Quelle: Eurostat Comext
| €2.5B |
| 8 | 🇰🇷South Korea | €1.2B | €720.8M | €1.9B |
| 9 | 🇨🇦Canada | €518.9M | €1.3B | €1.8B |
| 10 | 🇧🇷Brazil | €33.7M | €1.3B | €1.3B |
| 11 | 🇦🇺Australia | €58.6M | €1.2B | €1.3B |
| 12 | 🇲🇽Mexico | €69.4M | €1.0B | €1.1B |
| 13 | 🇮🇳India | €673.5M | €427.3M | €1.1B |
| 14 | 🇹🇷Turkey | €123.8M | €951.3M | €1.1B |
| 15 | 🇸🇬Singapore | €654.5M | €378.6M | €1.0B |
| 16 | 🇸🇦Saudi Arabia | €282K | €994.1M | €994.4M |
| 17 | 🇳🇴Norway | €129.4M | €602.7M | €732.1M |
| 18 | 🇮🇱Israel | €104.8M | €552.8M | €657.6M |
| 19 | 🇹🇼Taiwan | €10.3M | €604.5M | €614.8M |
| 20 | 🇦🇪United Arab Emirates | €10.0M | €553.3M | €563.3M |
| 21 | 🇺🇦Ukraine | €3.5M | €403.5M | €407.0M |
| 22 | 🇽🇸XS | €55.7M | €340.5M | €396.2M |
| 23 | 🇻🇳Vietnam | €10.9M | €357.6M | €368.5M |
| 24 | 🇿🇦South Africa | €4.9M | €342.8M | €347.7M |
| 25 | 🇨🇴Colombia | €1.2M | €341.5M | €342.7M |
| 26 | 🇪🇬Egypt | €33.7M | €273.0M | €306.7M |
| 27 | 🇹🇭Thailand | €13.4M | €287.3M | €300.7M |
| 28 | 🇦🇷Argentina | €23.7M | €257.2M | €280.9M |
| 29 | 🇰🇿Kazakhstan | €440K | €251.5M | €251.9M |
| 30 | 🇲🇾Malaysia | €5.3M | €241.2M | €246.5M |
| €1.8B |
| €2.6B |
| €4.5B |
| 5 | Other | €603.6M | €3.5B | €4.1B |
| 6 | Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale | €3.1B | €553.2M | €3.6B |
| 7 | - | €91.3M | €2.1B | €2.2B |
| 8 | Other | €372.3M | €1.4B | €1.7B |
| 9 | Other | €618.0M | €1.0B | €1.7B |
| 10 | Other, containing antibiotics | €278.1M | €896.7M | €1.2B |
| 11 | Containing corticosteroid hormones, their derivatives or structural analogues | €193.7M | €940.3M | €1.1B |
| 12 | Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale | €317.0M | €227.7M | €544.7M |
| 13 | Other | €109.6M | €404.4M | €514.0M |
| 14 | Vaccines for veterinary medicine | €61.5M | €416.3M | €477.8M |
| 15 | Opacifying preparations for X-ray examinations; diagnostic reagents designed to be administered to the patient | €25.8M | €432.5M | €458.3M |
| 16 | Other, containing vitamins or other products of heading|2936 | €72.2M | €276.1M | €348.3M |
| 17 | Other | €82.5M | €264.7M | €347.3M |
| 18 | Dental cements and other dental fillings; bone reconstruction cements | €119.6M | €227.3M | €346.9M |
| 19 | Adhesive dressings and other articles having an adhesive layer | €131.0M | €210.0M | €341.0M |
| 20 | Chemical contraceptive preparations based on hormones, on other products of heading|2937|or on spermicides | €2.2M | €335.1M | €337.3M |